JP2017502957A5 - - Google Patents

Download PDF

Info

Publication number
JP2017502957A5
JP2017502957A5 JP2016543097A JP2016543097A JP2017502957A5 JP 2017502957 A5 JP2017502957 A5 JP 2017502957A5 JP 2016543097 A JP2016543097 A JP 2016543097A JP 2016543097 A JP2016543097 A JP 2016543097A JP 2017502957 A5 JP2017502957 A5 JP 2017502957A5
Authority
JP
Japan
Prior art keywords
group
optionally substituted
alkyl
substituents selected
groups
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016543097A
Other languages
English (en)
Japanese (ja)
Other versions
JP6454349B2 (ja
JP2017502957A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2014/084752 external-priority patent/WO2015099196A1/en
Publication of JP2017502957A publication Critical patent/JP2017502957A/ja
Publication of JP2017502957A5 publication Critical patent/JP2017502957A5/ja
Application granted granted Critical
Publication of JP6454349B2 publication Critical patent/JP6454349B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016543097A 2013-12-26 2014-12-25 モノアシルグリセロールリパーゼ（ｍａｇｌ）阻害剤としての４−（ピペラジン−１−イル）−ピロリジン−２−オン化合物 Active JP6454349B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2013269244 2013-12-26
JP2013269244 2013-12-26
PCT/JP2014/084752 WO2015099196A1 (en) 2013-12-26 2014-12-25 4-(piperrazin-1-yl)-pyrrolidin-2-one compounds as monoacylglycerol lipase (magl) inhibitors

Publications (3)

Publication Number Publication Date
JP2017502957A JP2017502957A (ja) 2017-01-26
JP2017502957A5 true JP2017502957A5 (https=) 2017-12-07
JP6454349B2 JP6454349B2 (ja) 2019-01-16

Family

ID=52434920

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016543097A Active JP6454349B2 (ja) 2013-12-26 2014-12-25 モノアシルグリセロールリパーゼ（ｍａｇｌ）阻害剤としての４−（ピペラジン−１−イル）−ピロリジン−２−オン化合物

Country Status (4)

Country Link
US (1) US9624170B2 (https=)
EP (1) EP3087067B1 (https=)
JP (1) JP6454349B2 (https=)
WO (1) WO2015099196A1 (https=)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3152198B1 (en) * 2014-06-09 2019-02-27 Takeda Pharmaceutical Company Limited Radiolabeled compounds
ES2730112T3 (es) 2015-03-09 2019-11-08 Bristol Myers Squibb Co Lactamas como inhibidores de ROCK
US10106556B2 (en) 2015-03-30 2018-10-23 Takeda Pharmaceutical Company Limited Heterocyclic compound
AU2016295604B2 (en) 2015-07-23 2019-08-01 Glaxosmithkline Intellectual Property Development Limited Compounds
WO2017046794A1 (en) * 2015-09-14 2017-03-23 The National Institute for Biotechnology in the Negev Ltd. Novel piperazine and piperidine derivatives, their synthesis and use thereof in inhibiting vdac oligomerization, apoptosis and mitochondria dysfunction
US10434099B2 (en) * 2016-09-22 2019-10-08 The National Institute for Biotechnology in the Negev Ltd. Methods for treating central nervous system disorders using VDAC inhibitors
US10787423B2 (en) 2015-09-14 2020-09-29 The National Institute For Biotechnolgy In The Negev Ltd. Piperazine and piperidine derivatives, their synthesis and use thereof in inhibiting VDAC oligomerization, apoptosis and mitochondria dysfunction
JP6938485B2 (ja) 2015-10-14 2021-09-22 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 選択的ｎｒ２ｂアンタゴニスト
ES2804580T3 (es) 2016-03-31 2021-02-08 Takeda Pharmaceuticals Co Compuesto heterocíclico
WO2017170830A1 (ja) 2016-03-31 2017-10-05 武田薬品工業株式会社 複素環化合物
US10927105B1 (en) 2017-05-23 2021-02-23 Lundbeck La Jolla Research Center, Inc. Pyrazole MAGL inhibitors
JOP20190267A1 (ar) 2017-05-23 2019-11-18 Lundbeck La Jolla Research Center Inc مثبطات بيرازول magl
DK3630744T3 (da) 2017-05-23 2023-03-06 H Lundbeck As Pyrazol-magl-inhibitorer
CN107397955A (zh) * 2017-08-23 2017-11-28 上海黛妆国际贸易有限公司 黑色素基因抑制剂
BR112020005720A2 (pt) 2017-09-29 2020-10-20 Takeda Pharmaceutical Company Limited composto ou sal, medicamento, métodos para inibir monoacilglicerol lipase e para a profilaxia ou o tratamento de doença de alzheimer, doença de parkinson, doença de huntington, esclerose lateral amiotrófica, esclerose múltipla, distúrbio de ansiedade, dor, epilepsia ou depressão, e, uso do composto ou sal.
AR113967A1 (es) 2017-12-18 2020-07-01 Gruenenthal Gmbh Pirrolidinamidas i sustituidas
TW201927769A (zh) * 2017-12-18 2019-07-16 德商歌林達有限公司 經取代之吡咯啶醯胺ｉｉ
KR20200143376A (ko) 2018-03-13 2020-12-23 샤이어 휴먼 지네틱 테라피즈 인크. 혈장 칼리크레인 억제제로서의 치환된 이미다조피리딘 및 이의 용도
HRP20240935T1 (hr) * 2018-06-27 2024-11-22 Ptc Therapeutics, Inc. Heterociklični i heteroaril spojevi za liječenje huntingtonove bolesti
TW202028209A (zh) * 2018-09-27 2020-08-01 大陸商重慶複創醫藥研究有限公司 作為RET激酶抑制劑的取代的咪唑[1,2-a]吡啶和[1,2,4]三唑[1,5-a]吡啶化合物
JP7446316B2 (ja) 2019-01-11 2024-03-08 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 置換ピロリジンアミドｉｉｉ
CN114667289B (zh) 2019-09-18 2025-08-26 武田药品工业有限公司 杂芳基血浆激肽释放酶抑制剂
EP4031547B1 (en) 2019-09-18 2024-07-17 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof
EP3892614A1 (en) 2020-04-07 2021-10-13 Sanofi (1h-indol-5-yl)acrylamide derivatives as inhibitors of tead proteins and the hippo-yap1/taz signaling cascade for the treatment of cancer
US20230140808A1 (en) 2020-04-07 2023-05-04 Sanofi (1 H-Indol-5-YL)Acrylamide Derivatives as Inhibitors of Tead Proteins and the Hippo-YAP1/TAZ Signaling Cascade for the Treatment of Cancer
CN117396473A (zh) * 2021-03-17 2024-01-12 武田药品工业株式会社 血浆激肽释放酶的咪唑并吡啶基抑制剂
US20240382482A1 (en) * 2021-03-17 2024-11-21 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors
EP4333982A1 (en) * 2021-05-06 2024-03-13 Exscientia Al Limited Pkc-theta modulators
JP2024536718A (ja) * 2021-09-03 2024-10-08 エフ． ホフマン－ラ ロシュ アーゲー Ｍａｇｌ阻害剤
CA3242372A1 (en) 2021-12-29 2023-07-06 Psy Therapeutics, Inc. Inhibiting monoacylglycerol lipase (magl)

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1445792A1 (de) 1964-12-18 1969-01-02 Bayer Ag Verfahren zur Herstellung von Iminopyrrolidonen
WO2006013049A2 (en) * 2004-08-02 2006-02-09 F.Hoffmann-La Roche Ag Benzyloxy derivatives as maob inhibitors
JP2009275020A (ja) * 2008-05-16 2009-11-26 Institute Of Physical & Chemical Research 細胞増殖阻害剤
WO2010124122A1 (en) 2009-04-22 2010-10-28 Janssen Pharmaceutica Nv Heteroaromatic and aromatic piperazinyl azetidinyl amides as monoacylglycerol lipase inhibitors
US8455476B2 (en) 2009-04-22 2013-06-04 Janssen Pharmaceutica, Nv Azetidinyl diamides as monoacylglycerol lipase inhibitors
AU2010238745A1 (en) 2009-04-22 2011-11-10 Janssen Pharmaceutica Nv Heteroaromatic and aromatic piperazinyl azetidinyl amides as monoacylglycerol lipase inhibitor
WO2011041713A2 (en) * 2009-10-02 2011-04-07 Glaxosmithkline Llc Piperazinyl antiviral agents
WO2011050284A1 (en) * 2009-10-23 2011-04-28 Glaxosmithkline Llc Pyrazolylpyridine antiviral agents
RU2013114771A (ru) 2010-09-03 2014-10-10 Янссен Фармацевтика Нв Диамиды азетидинила как ингибиторы моноацилглицерол липазы
JP2013537920A (ja) 2010-09-27 2013-10-07 ヤンセン ファーマシューティカ エヌ．ベー． モノアシルグリセロールリパーゼ阻害剤としてのオキソピペラジン−アゼチジンアミド及びオキソジアゼピン−アゼチジンアミド
WO2012054716A1 (en) 2010-10-22 2012-04-26 Janssen Pharmaceutica Nv. Piperidin-4-yl-azetidine diamides as monoacylglycerol lipase inhibitors
CA2850100A1 (en) 2011-09-30 2013-04-04 Janssen Pharmaceutica Nv Monoacylglycerol lipase inhibitors for the treatment of metabolic diseases and related disorders
US8987247B2 (en) 2011-09-30 2015-03-24 Janssen Pharmaceutica Nv Monoacylglycerol lipase inhibitors for the treatment of metabolic diseases and related disorders
CA2866302A1 (en) * 2012-03-19 2013-09-26 Abide Therapeutics, Inc. Carbamate compounds and of making and using same

Similar Documents

Publication Publication Date Title
JP2017502957A5 (https=)
HRP20201171T1 (hr) Derivati izoindolin-1-ona kao modulatori aktivnosti pozitivnog alosternog modulatora kolinergijskog muskarinskog m1 receptora za liječenje alzheimerove bolesti
CO2020001860A2 (es) Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
Sun et al. The “memory kinases”: roles of PKC isoforms in signal processing and memory formation
CN109963854A (zh) 杂芳基并[4,3-c]嘧啶-5-胺类衍生物、其制备方法及其在医药上的应用
CO2019007711A2 (es) N-[4-fluoro-5-[[(2s,4s)-2-metil-4-[(5-metil-1,2,4-oxadiazol-3-il)metoxi]-1-piperidil]metil]tiazol-2-il]acetamida como inhibidor de oga
HRP20201216T1 (hr) PRIPRAVCI I POSTUPCI ZA LIJEČENJE POREMEĆAJA CNS-a
EA202190802A3 (ru) Производные пиразолопиридина, обладающие эффектом агониста рецептора glp-1
FI3406609T3 (fi) Bisyklisiä atsayhdisteitä muskariinireseptorin agonisteina
EA201791239A8 (ru) ТЕТРАГИДРОПИРИДО[3,4-b]ИНДОЛОВЫЕ МОДУЛЯТОРЫ ЭСТРОГЕНОВЫХ РЕЦЕПТОРОВ И ИХ ПРИМЕНЕНИЕ
EA201890001A1 (ru) Замещенные гетероциклические производные как ингибиторы циклинзависимой киназы (cdk)
JP2010534647A5 (https=)
MX2016012687A (es) Derivados de 2,4-tiazolidindiona en el tratamiento de trastornos del sistema nervioso central.
EP3541790C0 (en) 3-(2-(4-PHENYLPIPERAZIN-1-YL)ETHYL)-2-OXA-8-AZASPIRO[4.5]DECAN-1-ONE DERIVATIVES AND SIMILAR COMPOUNDS AS 5-HYDROXYTRYPTAMINE (5-HT7) RECEPTOR 7 MODULATORS FOR THE TREATMENT OF PE, INFLAMMATORY BOWEL DISEASE, CIRCADIAN RHYTHM DISORDER, OR DEPRESSION
FI3546462T3 (fi) Uusi oksoisokinoliinijohdannainen
CL2014001772A1 (es) Compuestos derivados de (furano/pirano)-[2,3, b]piridin-amida, antagonistas del receptor p2x7; composicion farmaceutica; y su uso para el tratamiento del dolor, enfermedades neurodegenerativas, neuroinflamatorias, entre otras.
RU2017120217A (ru) 2-амино-5,5-дифтор-6-(фторметил)-6-фенил-3,4,5,6-тетрагидпропиридины в качестве ингибиторов bace1
HUE067669T2 (hu) 7-fenoxi-N-(3-azabiciklo[3.2.1]oktán-8-il)-6,7-dihidro-5H-pirrolo[1,2-b][1,2,4]triazol-2-amin származékok és rokon vegyületek, mint gamma-szekretáz modulátorok az Alzheimer-kór kezelésére
RU2017112989A (ru) Соединения и способы
MX387775B (es) Derivado de 2-acilaminotiazol o sal del mismo.
CL2015003196A1 (es) Derivados de pirrolo[2,3-d]pirimidina como agonistas del receptor cb2.
RU2014144951A (ru) Новое 1-замещенное производное индазола
EA202190431A1 (ru) Гетероароматические модуляторы nmda рецептора и их применение
AU2013260056A8 (en) Compounds with TRPV4 activity, compositions and associated methods thereof
EA201592247A1 (ru) 4-(5-(4-ХЛОРОФЕНИЛ)-2-(2-ЦИКЛОПРОПИЛАЦЕТИЛ)-1,4-ДИМЕТИЛ-1H-ПИРРОЛ-3-ИЛ)БЕНЗОЛСУЛЬФОНАМИД В КАЧЕСТВЕ МОДУЛЯТОРА АЛЬФА-7 nAChR